Biomarkers in Multiple Myeloma

Recruiting now · Not applicable

Conditions studied: Hematological Patients, Newly Diagnosed Multiple Myeloma, Chemotherapy

In brief

The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by immunomodulatory drugs in combination with glucocorticoids. Moreover, the clinical outcome of MM is supposed to be correlated to the risk of thrombosis. At the biological level, a number of hemostasis abnormalities participate in increasing VTE incidence. Yet, data on predictive biomarkers linked to VTE are limited.

Key facts

Study ID

NCT05259553

Run by

Centre Hospitalier Universitaire de Saint Etienne

People needed

70

Starts

2022-05-20

Expected to finish

2027-10-30

Last updated by the study team

2025-04-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient affiliated to a social security regimen or beneficiary of the same
• Signed written informed consent form
• Confirmed diagnosis of de novo multiple myeloma, non-previously treated and requiring treatment.

You may not qualify if…

• Pregnant women
• Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent
• Refusing participation
• Patient whose follow-up or life expectancy is less than 6 months.

Where it is running

• Hospices Civils de Lyon — Lyon, France (enrolling)
• CHU de Saint-Etienne — Saint-Etienne, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.